Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Positive results for DNA-based Zika Vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:11pm CEST

All 40 healthy volunteers in the study developed Zika-specific antiboides after three doses, researchers said.

The companies GLS-5700 is a DNA-based vaccine that is made by reproducing sections of the Zika virus genome and loading them onto a plasmid, unlike standard vaccines that usually use inactivated or killed versions of a virus.

After the vaccine is injected into a patient, a device is used to generate electrical impulses that create small pores in cells that allow the DNA to get inside.

Sanofi ended development on its more traditional Zika vaccine last month, while Takeda is still working on its own product.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
12:25p SANOFI : earmarks 170m for new French vaccines facility
12:15p SANOFI SA (ADR)(NYSE : SNY), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Dupixen..
10:07a REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
10:07a SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17 AIMMUNE THERAPEUTICS : Announces Clinical Collaboration to Study AR101 with Rege..
10/17 SANOFI : New influenza vaccine facility, first of its kind in France
10/17 ROCHE : Cambridge biotech signs deal to take on superbugs
10/17 AIMMUNE THERAPEUTICS : Regeneron/Sanofi, Aimmune collaborate on peanut allergy c..
10/16 SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in ..
More news
News from SeekingAlpha
09:36a HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
10/17 The Medicines Company May Not Be The Best Investment In 2017
10/16 Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients ..
10/16 MANNKIND CORPORATION : Can Afrezza Improved Labeling Fuel A Successful Comeback?
10/16 Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophi..
Financials (€)
Sales 2017 36 186 M
EBIT 2017 9 602 M
Net income 2017 8 042 M
Debt 2017 5 004 M
Yield 2017 3,61%
P/E ratio 2017 12,98
P/E ratio 2018 17,43
EV / Sales 2017 3,07x
EV / Sales 2018 2,99x
Capitalization 106 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 87,0 €
Spread / Average Target 3,7%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.71%124 607
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423